bf/NASDAQ:INKT_icon.jpeg

NASDAQ:INKT

MiNK Therapeutics, Inc.

  • Stock

7.40

−0.70%

−6.80

USD last updated 13/08 01:59:42

Last Close

14.20

12/08 22:32

Market Cap

30.21M

Beta: -

Volume Today

858

Avg: 87.89K

PE Ratio

0.21

PFCF: −1.71

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.6-0.5-0.4-0.3-0.2-0.12020-03-302020-12-312022-03-182023-08-102024-08-082025-11-12

    Revenue (Estimate*)

    500M1B1.50B2B2.50B2020-03-302020-12-312022-03-182023-08-102024-08-082025-11-12

    *Estimate based on analyst consensus